{"created":"2023-06-20T14:25:04.460469+00:00","id":141,"links":{},"metadata":{"_buckets":{"deposit":"6446ce41-f9f8-46e1-b5d0-e20bc7a831c4"},"_deposit":{"created_by":3,"id":"141","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"141"},"status":"published"},"_oai":{"id":"oai:dmu.repo.nii.ac.jp:00000141","sets":["81:26"]},"author_link":["444","443"],"item_2_biblio_info_12":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2003-07-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"179","bibliographicPageStart":"173","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"Dokkyo journal of medical sciences"}]}]},"item_2_description_10":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"急性心筋梗塞(AMI)の治療法として遺伝子変異型組織プラスミノゲンアクチベーター(mutant t-PA)であるモンテプラーゼ27,500 IU/kgの単回静脈先行投与と経皮的冠動脈形成術(PCI)の併用療法の妥当性を血漿プラスミノゲンアクチベーターインヒビター-1(PAI-1)動態から検討した。AMI患者126例を併用療法群(C群)58例とPCI単独施行群(P群)68例とに無作為に割付けし,血漿PAI-1抗原量をLPIA法で経時的に測定した。C群では初回冠動脈造影時TIMI II-IIIが得られた症例はTIMI 0-Iだった症例に比べ,搬入時PAI-1抗原量が有意に低値であった(P<0.05)。PAI-1抗原量は両群とも搬入時に正常基準値より高値であり,PCI後さらに上昇を認め24時問後までにピーク(C群:147.6±16.2%,P群:195.6±28.5%)を示した。しかし,その経時変化は両群間で有意差はなかった。ステント非留置症例では,48時間後のPAI-1抗原量はP群ではC群に比べ有意に(P<0.05)高値であった。以上の結果より,AMI発症早期に通常量のmutant t-PAであるモンテプラーゼの単回静脈投与は血漿PAI-1動態に影響を与えず,また本剤の先行投与はPCIとの併用療法でPAI-1動態に影響しないことが明らかとなった。","subitem_description_type":"Other"}]},"item_2_description_11":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"We investigated the clinical usefulness of combination therapy of single bolus injection of intravenous mutant t-PA (Monteplase 27500 IU/kg weight) and PCI for treatment of AMI in the light of PAI-ikinetics. Consecutive l26patients were randomly assigned to PCI following pre-treatment with intravenous Monteplase (group C ; n = 58) or receive direct PCI (group P ; n 68). The method of plasma PM-1 anti-gen was the latex photometric immunoassay (LPLA). In group C, the PAI-1 antigen levels at admission were lower in patients with TIMI II-III flow than in those with TIMI 0-I by first coronary angiography (P < 0.05). In both groups, the PM-1 antigen levels at admission were higher than normal value and increased maximally until 24 hrs (Group C 147.6 ± 16.2%, Group P : 195.6 ± 28.5%). Serial change patterns in the PMI-1 level were similar in both groups. In patients without stenting, PAI-1 levels after 48 hours were significantly higher Group P than Group C (P < 0.05). These results suggested that Monteplase as a pretreatment of AMI before PCI did not influenced in light of PMI-1 kinetics.","subitem_description_type":"Other"}]},"item_2_description_8":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著","subitem_description_type":"Other"}]},"item_2_description_9":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Original","subitem_description_type":"Other"}]},"item_2_source_id_1":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA00629581"}]},"item_2_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03855023","subitem_source_identifier_type":"ISSN"}]},"item_2_text_6":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"獨協医科大学越谷病院循環器内科"}]},"item_2_text_7":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine"}]},"item_2_title_3":{"attribute_name":"論文名よみ","attribute_value_mlt":[{"subitem_title":"プラスミノゲン アクチベーター インヒビター-1(PAI-1) ドウタイ カラ ミタ キュウセイ シンキン コウソク ジ ノ カンケッカン ケイセイジュツ ニオケル モンテプラーゼ センコウ トウヨ ノ エイキョウ"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"渡辺, 淳一郎"},{"creatorName":"ワタナベ, ジュンイチロウ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Watanabe, Junichiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-05-24"}],"displaytype":"detail","filename":"KJ00000010472.pdf","filesize":[{"value":"697.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00000010472.pdf","url":"https://dmu.repo.nii.ac.jp/record/141/files/KJ00000010472.pdf"},"version_id":"e94599ba-8c12-4c83-a542-97f76c57ccae"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"急性心筋梗塞(AMI)"},{"subitem_subject":"遺伝子変異型組織プラスミノゲンアクチベーター(mutant t-PA)"},{"subitem_subject":"経皮的冠動脈形成術(PCI)"},{"subitem_subject":"併用療法"},{"subitem_subject":"プラスミノゲンアクチベーターインヒビター-1(PAI-1)"},{"subitem_subject":"acute myocardial infarction (AMI)","subitem_subject_language":"en"},{"subitem_subject":"mutant tissue-plasminogen activator (mutant t-PA)","subitem_subject_language":"en"},{"subitem_subject":"perctaneous coronary intervention (PCI)","subitem_subject_language":"en"},{"subitem_subject":"combination therapy","subitem_subject_language":"en"},{"subitem_subject":"plasminogen activator inhibitor-1 (PAI-1)","subitem_subject_language":"en"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"プラスミノゲンアクチベーターインヒビター-1(PAI-1)動態からみた急性心筋梗塞時の冠血管形成術におけるモンテプラーゼ先行投与の影響","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"プラスミノゲンアクチベーターインヒビター-1(PAI-1)動態からみた急性心筋梗塞時の冠血管形成術におけるモンテプラーゼ先行投与の影響"},{"subitem_title":"The Efficacy of Monteplase as a Pretreatment of Myocardial Infarction (AMI) Before Perctaneous Transluminal Coronary Intervention (PCI) in Light of Plasminogen Activator Inhibitor-1 (PAT-1) kinetics","subitem_title_language":"en"}]},"item_type_id":"2","owner":"3","path":["26"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-05-24"},"publish_date":"2017-05-24","publish_status":"0","recid":"141","relation_version_is_last":true,"title":["プラスミノゲンアクチベーターインヒビター-1(PAI-1)動態からみた急性心筋梗塞時の冠血管形成術におけるモンテプラーゼ先行投与の影響"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-20T16:23:04.878907+00:00"}